TherapeuticsMD, Inc.
TXMD
$1.20
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.56% | 32.87% | 1,132.08% | -46.45% | -24.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.56% | 32.87% | 1,132.08% | -46.45% | -24.76% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 25.56% | 32.87% | 1,132.08% | -46.45% | -24.76% |
| SG&A Expenses | -18.23% | -40.45% | -17.61% | -55.66% | -56.74% |
| Depreciation & Amortization | -28.57% | -84.30% | -26.15% | 40.63% | 392.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.18% | -53.67% | -18.26% | -51.43% | -52.81% |
| Operating Income | 31.44% | 80.63% | 51.55% | 52.31% | 57.18% |
| Income Before Tax | 17.43% | 105.24% | 60.46% | 56.50% | 64.98% |
| Income Tax Expenses | -- | 27.91% | -- | -- | -- |
| Earnings from Continuing Operations | 21.38% | 107.40% | 60.46% | 56.50% | 64.98% |
| Earnings from Discontinued Operations | -122.67% | -79.03% | 97.84% | -- | 105.80% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.04% | 128.54% | 81.97% | 54.85% | 79.63% |
| EBIT | 31.44% | 80.63% | 51.55% | 52.31% | 57.18% |
| EBITDA | 31.81% | 85.45% | 53.59% | 57.36% | 61.78% |
| EPS Basic | 11.16% | 127.38% | 83.28% | 59.99% | 82.78% |
| Normalized Basic EPS | 28.31% | 29.88% | 63.37% | 61.86% | 70.41% |
| EPS Diluted | 3.30% | 126.16% | 83.02% | 60.63% | 82.93% |
| Normalized Diluted EPS | 28.31% | 29.88% | 63.37% | 61.86% | 70.41% |
| Average Basic Shares Outstanding | 0.17% | 4.45% | 7.77% | 12.85% | 18.23% |
| Average Diluted Shares Outstanding | 0.17% | 4.45% | 7.77% | 12.85% | 18.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |